The global neurology clinical trials market size is expected to reach USD 7.4 billion by 2028. The market is expected to expand at a CAGR of 5.5% from 2021 to 2028.
This is largely attributed to big pharma companies conducting innovative trials in neurology, increased government funding from the National Institute of Neurological Disorders and Stroke (NINDS), and stringent regulatory requirements pertaining to clinical trials.
Neuroscience continues to receive a healthy level of early investment. It received USD 1.5 billion in venture capital funding in 2018, second only to cancer, indicating that investors expect a large pharma acquisition to pay off in the near future. As the industry strives to move past the many late-stage clinical failures of recent years, early diagnosis of diseases is attracting investment and driving deal-making in the complex neuroscience sector, particularly for pain and Alzheimer's disease.
In terms of deal volume, no other therapy area comes close to matching oncology, but neuroscience is among the nearest contenders. Despite a drop in total expected value in 2017, the number of neuroscience-related licensing deals has gradually climbed over the last decade.
The vast majority of neuroscience agreements ~90%have a primary neurological focus, which corresponds to the level of R&D activity in the two disciplines.
Many experimental therapeutics require dosage by on-site administration and carefully scheduled outcome measure evaluations hence, the COVID-19 pandemic has significantly harmed the implementation of the precise procedures required to establish proof of safety and efficacy.
The COVID-19 has resulted in the shutdown of the network of centers conducting stroke clinical trials. This was followed by a phased research restart plan that took local circumstances and regulatory oversight into account. This approach was successful in a reengaging research effort to some extent in all but one of the ongoing investigations within 55 days.
The phase II segment dominated the market and accounted for a maximum revenue share of 36.7% in 2020. Between 1999 and 2020, 8,205 CNS trials were conducted, with 609 trials being conducted in 2020.
The interventional segment held the largest market revenue share of 81.1% in 2020.
The Huntington's disease segment is anticipated to register the fastest CAGR of 6.0% over the forecast period. This is largely due to the high prevalence of the disease around the world.
North America dominated the market and accounted for a revenue share of 45.8% in 2020. The rising prevalence of neurological disorders and the presence of a large number of players in clinical trials drive the market in the region.
Key Topics Covered:
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Neurology Clinical Trials Market: Variables, Trends, & Scope 3.1 Market Segmentation and Scope 3.2 Market Dynamics 3.2.1 Market Driver Analysis 18.104.22.168 Increasing neurological disease, such as dementia, stroke, and peripheral neuropathy 22.214.171.124 Increasing R&D investments 126.96.36.199 Stringent Regulatory Requirements 3.2.2 Market Restraint Analysis 188.8.131.52 High Failure Rates of Trials 184.108.40.206 Rising Cost of Clinical Trials 3.3 Penetration & Growth Prospect Mapping 3.4 COVID-19 Impact on the Market 3.5 Major Deals and Strategic Alliances Analysis 3.6 Neurology Clinical Trials: Market Analysis Tools 3.6.1 Industry Analysis - Porter's 3.6.3 PESTEL Analysis
Chapter 4 Neurology Clinical Trials Market: Phase Segment Analysis 4.1 Neurology Clinical Trials Market: Phase Market Share Analysis, 2020 & 2028 4.2 Phase I 4.2.1 Phase I Market, 2016 - 2028 (USD Million) 4.3 Phase II 4.3.1 Phase II Market, 2016 - 2028 (USD Million) 4.4 Phase III 4.4.1 Phase III Market, 2016 - 2028 (USD Million) 4.5 Phase IV 4.5.1 Phase IV Market, 2016 - 2028 (USD Million)